-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Cytokinetics, Lowers Price Target to $100

Benzinga·11/20/2026 17:54:02
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and lowers the price target from $103 to $100.